

Socioeconomic factors associated with poor medication adherence for patients with type 2 diabetes

Marie Ekenberg¹, Miriam Qvarnström¹, Anders Sundström¹, Mats Martinell², Björn Wettermark¹

*1 Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.
marie.ekenberg@farmaci.uu.se.*

2 Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Supplementary Table S1 Antidiabetic agents and ATC codes included in the dataset of prescribed medications.

Antidiabetic agents	ATC codes
Insulin and analogues	A10A
Insulins and analogues for injection, fast-acting	A10AB
Insulins and analogues for injection, intermediate-acting	A10AC
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting	A10AD
Insulins and analogues for injection, long-acting	A10AE
Blood glucose lowering agents excluding Insulin	A10B
Biguanide derivatives	A10BA
Metformin	A10BA02
Sulfonylurea compounds	A10BB
Glibenclamide	A10BB01
Glipizide	A10BB07
Glimepiride	A10BB12
Peroral diabetes drugs, combinations	A10BD
metformin and sitagliptin	A10BD07
metformin and vildagliptin	A10BD08
metformin and linagliptin	A10BD11
metformin and empagliflozin	A10BD20
metformin and ertugliflozin	A10BD23
Glycosidase inhibitors	A10BF
Acarbose	A10BF01
Thiazolidinediones	A10BG
Pioglitazone	A10BG03
Dipeptidyl peptidase-4 (DPP-4) inhibitors	A10BH
Sitagliptin	A10BH01
Saxagliptin	A10BH03
Linagliptin	A10BH05
Glucagon-like peptide-1 (GLP-1) analogues	A10BJ
Liraglutid	A10BX07 (before 2017), A10BJ02 (after 2017)
Dulaglutid	A10BJ05
Semaglutide	A10BJ06
Sodium-glucose co-transporter 2 (SGLT2) inhibitors	A10BK
Dapagliflozin	A10BX09 (before 2017), A10BK01 (after 2017)
Empagliflozin	A10BK03
Other blood glucose lowering agents excluding Insulin	A10BX
Repaglinide	A10BX02